Merck Serono - PDFSEARCH.IO - Document Search Engine

Merck Serono
Results: 49

#	Item
11	News Release June 8, 2011 Affectis Pharmaceuticals and Merck Serono Announce an Agreement to Develop Oral Drugs for Neurodegenerative Diseases Merck Serono to develop compounds from Affectis targeting P2X7 receptors Add to Reading List Source URL: www.bayernkapital.de Language: English - Date: 2011-06-14 06:59:15 Merck KGaA Pharmacology Serono Merck & Co. Serostim Kommanditgesellschaft auf Aktien Interferon beta-1a Merck Manual of Diagnosis and Therapy Genset Corporation Merck Pharmaceutical industry Pharmaceutical sciences
12	New leaders appointed at the International Federation of Pharmaceutical Manufacturers & Associations Masafumi Nogimori and Stefan Oschmann become IFPMA Acting President and Acting Vice President respectively Geneva, 14 Add to Reading List Source URL: www.jpma.or.jp Language: English - Date: 2013-06-30 20:56:30 Merck Pharmaceutics IFPMA Clinical research Clinical trial Astellas Pharma Merck Serono Serono Merck KGaA Pharmaceutical sciences Pharmaceutical industry Pharmacology
13	Track & trace in the pharmaceutical industry Sébastien Mauel Head of Product Security Table of contents Add to Reading List Source URL: www.2ndchance.info Language: English - Date: 2014-02-04 17:41:24 Growth hormones Automatic identification and data capture Merck Merck Serono Packaging Serono Serostim Packaging and labeling Epedigree Technology Business Pharmaceutical industry
14	BioMed Research International Special Issue on Biotechnology and Biosimilars in Emerging Countries CALL FOR PAPERS Add to Reading List Source URL: downloads.hindawi.com Language: English - Date: 2015-03-09 05:49:59 Merck Clinical research Biosimilar Drugs Biologic Mylan Serono Merck KGaA Pharmaceutical industry Pharmacology Pharmaceutical sciences Biotechnology
15	INVESTOR FACT SHEET Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages Add to Reading List Source URL: www.ablynx.com Language: English - Date: 2015-03-23 08:29:54 Boehringer Ingelheim Technology Ablynx Serono Novartis Pharmaceutical industry Pharmaceutical sciences Merck
16	ANNUAL REPORT 2014 INDEX 1. BUSINESS SECTION Add to Reading List Source URL: www.ablynx.com Language: English - Date: 2015-04-07 11:01:36 Monoclonal antibodies Merck Single-domain antibody Serono Pharmaceutical industry Psoriasis Pharmacology Ablynx Vrije Universiteit Brussel Pharmaceutical sciences
17	REGULATED INFORMATION FMR LLC PROVIDES NOTIFICATION OF SHAREHOLDING IN ABLYNX GHENT, Belgium, 15 April 2015 – Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May Add to Reading List Source URL: hugin.info Language: English - Date: 2015-04-14 12:00:52 Ethics Pharmaceutical industry Business law Monoclonal antibodies Forward-looking statement Single-domain antibody Ghent Serono Merck & Co. Vrije Universiteit Brussel Business Ablynx
18	ABLYNX ANNOUNCES PUBLICATION OF 2014 ANNUAL REPORT AND LAUNCH OF NEW WEBSITE GHENT, Belgium, 7 April 2015 – Ablynx [Euronext Brussels: ABLX; OTC ABYLY] today announced the publication of its 2014 Annual Report which ca Add to Reading List Source URL: hugin.info Language: English - Date: 2015-04-07 11:47:27 Pharmaceutical industry Monoclonal antibodies Science Forward-looking statement Philosophy of science Single-domain antibody Ghent Merck Serono Merck & Co. Vrije Universiteit Brussel Ablynx Pharmaceutical sciences
19	Protecting Brands Globally™ FOR IMMEDIATE RELEASE Sproxil’s Founder & CEO Ashifi Gogo Named A Social Entrepreneur of the Year by the Schwab Foundation Cambridge, MA – Sproxil®, a leading provider of world-class br Add to Reading List Source URL: sproxil.com Language: English - Date: 2014-03-27 11:04:56 Business Counterfeit consumer goods Social enterprise Merck Entrepreneurship Social entrepreneurship Authentication Serono Schwab Foundation for Social Entrepreneurship Security Business software Sproxil
20	Public Summary Document Application No[removed]Cetuximab and KRAS mutation testing under MBS 73330 Applicant: Merck Serono Australia Pty Ltd Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-12-16 20:01:29 Bristol-Myers Squibb Cetuximab KRAS Panitumumab Oncogenes Gastrointestinal cancer Ras subfamily Colorectal cancer HRAS Medicine Biology Oncology